Controlled exposure to mite allergen for a dose-finding of dimethindene maleate (DMM).
The aim of the study was to develop a laboratory system to challenge mite allergic patients with physiological concentrations of Der p I in order to evaluate the efficacy of antiallergic drugs in mite allergic patients. A double-blind, placebo-controlled, cross-over study was designed with three consecutive sessions. Twelve patients with proven sensitivity to dust mite were treated with a single dose of dimethindene maleate in a FOAD formulation (4 and 8 mg vs. placebo) 12 h before a long-term challenge with mite allergen Der p I in the Vienna challenge chamber. Challenge was performed with a constant concentration of 40 ng Der p I per cubic meter of air for 4 h. Nasal parameters were recorded at 15 min intervals during long-term challenge. In comparison to placebo, dimethindene leads to a statistically significant reduction (p < 0.05) of the nasal response at both concentrations tested. The house-dust mite model in the Vienna challenge chamber thus proved to be a useful tool for drug investigations in mite allergies.
HNO-Universitätsklinik Währinger Gürtel, Wien, Austria.
F
F
Horak
S
S
Jäger
U
U
Berger
J
J
Toth
G
G
Nirnberger
H J
HJ
Kyrein
D
D
Rehn
J M
JM
Vix
D000328:Adult; D000403:Airway Resistance / Q000502:physiology; D000485:Allergens / Q000276:immunology*; D000818:Animals; D004115:Dimethindene / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004391:Dust / Q000009:adverse effects; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D008925:Mites / Q000276:immunology*; D015508:Nasal Obstruction / Q000188:drug therapy / Q000503:physiopathology; D011852:Radioallergosorbent Test
D000485:Allergens; D004391:Dust; D004115:Dimethindene